UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium.
UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium; WEL Research Institute, avenue Pasteur, 6, 1300 Wavre, Belgium.
Adv Drug Deliv Rev. 2023 Dec;203:115117. doi: 10.1016/j.addr.2023.115117. Epub 2023 Oct 26.
Oral administration is the preferred route of administration based on the convenience for and compliance of the patient. Oral nanomedicines have been developed to overcome the limitations of free drugs and overcome gastrointestinal (GI) barriers, which are heterogeneous across healthy and diseased populations. This review aims to provide a comprehensive overview and comparison of the oral nanomedicine biointeractions in the gastrointestinal tract (GIT) in health and disease (GI and extra-GI diseases) and highlight emerging strategies that exploit these differences for oral nanomedicine-based treatment. We introduce the key GI barriers related to oral delivery and summarize their pathological changes in various diseases. We discuss nanomedicine biointeractions in the GIT in health by describing the general biointeractions based on the type of oral nanomedicine and advanced biointeractions facilitated by advanced strategies applied in this field. We then discuss nanomedicine biointeractions in different diseases and explore how pathological characteristics have been harnessed to advance the development of oral nanomedicine.
口服给药是基于患者的便利性和顺应性而首选的给药途径。口服纳米药物的开发是为了克服游离药物的局限性,并克服胃肠道(GI)屏障,这些屏障在健康和患病人群中是不均匀的。本综述旨在全面概述和比较健康和疾病(GI 和非 GI 疾病)中胃肠道(GIT)中口服纳米药物的生物相互作用,并强调利用这些差异进行口服纳米药物治疗的新兴策略。我们介绍了与口服给药相关的关键 GI 屏障,并总结了各种疾病中它们的病理变化。我们通过描述基于口服纳米药物类型的一般生物相互作用以及该领域应用的先进策略所促进的先进生物相互作用,来讨论健康状态下 GIT 中的纳米药物生物相互作用。然后,我们讨论了不同疾病中的纳米药物生物相互作用,并探讨了如何利用病理特征来促进口服纳米药物的发展。